This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates
by Zacks Equity Research
NVAX stock jumps 17% after Q4 swings to a surprise profit on strong licensing revenues and lower costs, with sales soaring 67% year over year.
SNYPositive Net Change PFEPositive Net Change NVAXNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up
by Zacks Equity Research
VTRS beats Q4 estimates on 5% revenue growth, boosted by strong Brands sales and Greater China gains, while returning over $1B to shareholders in 2025.
ANIPNegative Net Change ALLOPositive Net Change CSTLNegative Net Change VTRSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change
by Zacks Equity Research
ALKS beats Q4 earnings and revenue estimates, but shares fall 7%. The company announces a CEO transition plan.
ALKSNegative Net Change ADMAPositive Net Change RCUSPositive Net Change CSTLNegative Net Change
biotechs earnings
ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance
by Zacks Equity Research
ADMA posts 18% Q4 revenue growth as Asceniv drives record 2025 sales, with 2026 revenues seen topping $635M and margins set to expand.
ANIPNegative Net Change ADMAPositive Net Change ALLOPositive Net Change CSTLNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues
by Zacks Equity Research
MIRM posts Q4 loss. Revenues jump 50% on strong Livmarli and bile acid drug sales, topping estimates in Q4 2025 and lifting shares.
ADMAPositive Net Change RCUSPositive Net Change MIRMPositive Net Change CSTLNegative Net Change
biotechs earnings
Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates
by Zacks Equity Research
SRPT posts a wider Q4 loss as Elevidys sales tumble, but revenues top estimates and 2026 guidance outlines a cautious recovery path.
RHHBYPositive Net Change SRPTNegative Net Change ARWRNegative Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals
Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y
by Zacks Equity Research
CPRX tops Q4 estimates as Firdapse and Agamree sales jump, lifting 2025 results and driving upbeat 2026 revenue guidance.
CPRXNegative Net Change USNAPositive Net Change CSTLNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
by Zacks Equity Research
Acadia beats Q4 EPS estimates as Nuplazid and Daybue lift revenues 9%, but sales miss and EU setback cloud trofinetide outlook with 2026 sales at $1.22-$1.28 billion.
USNAPositive Net Change ACADNegative Net Change CSTLNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View
by Zacks Equity Research
Revolution Medicines posts a wider-than-expected Q4 loss and sees 2026 operating expenses of $1.6B-$1.7B as it advances late-stage RAS pipeline studies.
BMYPositive Net Change SMMTPositive Net Change RVMDNegative Net Change TNGXNegative Net Change
biotechs earnings medical pharmaceuticals
Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss
by Zacks Equity Research
AMRN swings to Q4 profit and beats estimates, but revenues decline 21% as Vascepa sales slide and shares fall 9% on the mixed results.
AMRNNegative Net Change ANIPNegative Net Change ASRTNegative Net Change CSTLNegative Net Change
biotechs